159 related articles for article (PubMed ID: 37306026)
41. FTO demethylates YAP mRNA promoting oral squamous cell carcinoma tumorigenesis.
Li DQ; Huang CC; Zhang G; Zhou LL
Neoplasma; 2022 Jan; 69(1):71-79. PubMed ID: 34779644
[TBL] [Abstract][Full Text] [Related]
42. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
[TBL] [Abstract][Full Text] [Related]
43. FTO demethylates m6A modifications in CDKAL1 mRNA and promotes gastric cancer chemoresistance by altering mitochondrial dynamics.
Liu N; Liu C; Wang Z; Wang L; Wang J; Kong J
Clin Exp Pharmacol Physiol; 2023 Apr; 50(4):307-315. PubMed ID: 36628934
[TBL] [Abstract][Full Text] [Related]
44. FTO modifies the m6A level of MALAT and promotes bladder cancer progression.
Tao L; Mu X; Chen H; Jin D; Zhang R; Zhao Y; Fan J; Cao M; Zhou Z
Clin Transl Med; 2021 Feb; 11(2):e310. PubMed ID: 33634966
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms.
Zhuang X; Liu T; Wei L; Gao J
Front Pharmacol; 2023; 14():1260300. PubMed ID: 37822879
[No Abstract] [Full Text] [Related]
46. Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin.
Wang Y; Cheng Z; Xu J; Lai M; Liu L; Zuo M; Dang L
Bioengineered; 2021 Dec; 12(1):1874-1889. PubMed ID: 34076564
[TBL] [Abstract][Full Text] [Related]
47. ZEB1 promotes prostate cancer proliferation and invasion through ERK1/2 signaling pathway.
Song XF; Chang H; Liang Q; Guo ZF; Wu JW
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4032-4038. PubMed ID: 29028100
[TBL] [Abstract][Full Text] [Related]
48. The m
Li X; Li Y; Wang Y; He X
Cytokine; 2022 Nov; 159():156000. PubMed ID: 36058192
[TBL] [Abstract][Full Text] [Related]
49. m
Wang W; He Y; Zhai LL; Chen LJ; Yao LC; Wu L; Tang ZG; Ning JZ
Epigenetics; 2022 Dec; 17(12):1738-1752. PubMed ID: 35404184
[TBL] [Abstract][Full Text] [Related]
50. Long non-coding RNA
Fan MJ; Zou YH; He PJ; Zhang S; Sun XM; Li CZ
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31092700
[TBL] [Abstract][Full Text] [Related]
51. CircRNA DNA methyltransferase 1 silence inhibits breast cancer development by regulating micoRNA-485-3p/zinc finger E-box binding homeobox 1 axis.
Xie C; Li J; Xu C; Xiong W; Yuan X
J Obstet Gynaecol Res; 2021 Mar; 47(3):1068-1081. PubMed ID: 33403756
[TBL] [Abstract][Full Text] [Related]
52. FTO-Dependent N
Mathiyalagan P; Adamiak M; Mayourian J; Sassi Y; Liang Y; Agarwal N; Jha D; Zhang S; Kohlbrenner E; Chepurko E; Chen J; Trivieri MG; Singh R; Bouchareb R; Fish K; Ishikawa K; Lebeche D; Hajjar RJ; Sahoo S
Circulation; 2019 Jan; 139(4):518-532. PubMed ID: 29997116
[TBL] [Abstract][Full Text] [Related]
53. PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.
Zhang Y; Zhou X; Cheng X; Hong X; Jiang X; Jing G; Chen K; Li Y
Neoplasma; 2022 Dec; 69(6):1338-1348. PubMed ID: 36305690
[TBL] [Abstract][Full Text] [Related]
54. Long intergenic non-protein coding RNA 00858 participates in the occurrence and development of esophageal squamous cell carcinoma through the activation of the FTO-m6A-MYC axis by recruiting ZNF184.
Ke S; Wang J; Lu J; Fang M; Li R
Genomics; 2023 May; 115(3):110593. PubMed ID: 36868327
[TBL] [Abstract][Full Text] [Related]
55. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation.
Zhou S; Bai ZL; Xia D; Zhao ZJ; Zhao R; Wang YY; Zhe H
Mol Carcinog; 2018 May; 57(5):590-597. PubMed ID: 29315835
[TBL] [Abstract][Full Text] [Related]
56. The miR-27a-3p/FTO axis modifies hypoxia-induced malignant behaviors of glioma cells.
Du P; Meng L; Liao X; Liu Y; Mo X; Gong M; Liao Y
Acta Biochim Biophys Sin (Shanghai); 2023 Jan; 55(1):103-116. PubMed ID: 36718644
[TBL] [Abstract][Full Text] [Related]
57. MiR-1179 is downregulated in cervical cancer and its overexpression suppresses cancer cells invasion by targeting CHAF1A/ZEB1.
Lv F; Zhong Y; Sang L; Wu X
Acta Biochim Pol; 2021 Mar; 68(2):193-199. PubMed ID: 33740340
[TBL] [Abstract][Full Text] [Related]
58. FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells.
Zhao F; Ge F; Xie M; Li Z; Zang C; Kong L; Pu Y; Zheng X; Tan Y
Clin Exp Metastasis; 2022 Aug; 39(4):623-639. PubMed ID: 35524932
[TBL] [Abstract][Full Text] [Related]
59. FTO-mediated m6A demethylation of pri-miR-3591 alleviates osteoarthritis progression.
Liu W; Jiang T; Zheng W; Zhang J; Li A; Lu C; Lin Z
Arthritis Res Ther; 2023 Apr; 25(1):53. PubMed ID: 37005694
[TBL] [Abstract][Full Text] [Related]
60. The m6A demethylase FTO promotes keloid formation by up-regulating COL1A1.
Ren S; Ji Y; Wang M; Ye M; Huang L; Cai X
Ann Transl Med; 2023 Jan; 11(1):15. PubMed ID: 36760238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
